Joint action of miR‐126 and MAPK/PI3K inhibitors against metastatic melanoma
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12506
Abstract: Emerging data support the rationale of combined therapies in advanced melanoma. Specifically, the combined use of drugs with different mechanisms of action can reduce the probability of selecting resistant clones. To identify agents active against… read more here.
Keywords: combination; mir 126; pik; metastatic melanoma ... See more keywords
Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.773
Abstract: Vemurafenib is a BRAF kinase inhibitor indicated for the treatment of patients with BRAFV600 mutation–positive unresectable or metastatic melanoma and Erdheim‐Chester disease. This phase 1, open‐label, single‐arm study was designed to estimate absolute bioavailability of… read more here.
Keywords: mutation positive; bioavailability; absolute bioavailability; patients brafv600 ... See more keywords
Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation–Positive Malignancies
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.788
Abstract: This phase 1 open‐label, multicenter, 3‐period, fixed‐sequence study evaluated the effect of multiple doses of vemurafenib on the pharmacokinetics of 1 dose of tizanidine, a probe CYP1A2 substrate, in patients with BRAFV600 mutation–positive metastatic malignancy.… read more here.
Keywords: period; dose tizanidine; drug; vemurafenib ... See more keywords
Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma
Sign Up to like & getrecommendations! Published in 2017 at "Targeted Oncology"
DOI: 10.1007/s11523-017-0491-8
Abstract: BackgroundCirculating tumor DNA (ctDNA) has been reported as a prognostic marker in melanoma. In BRAF V600-mutant melanoma, a plasma under-exposure to vemurafenib could favor emerging resistance but no biological data are available to support this… read more here.
Keywords: melanoma; vemurafenib plasma; ctdna; vemurafenib ... See more keywords
Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma
Sign Up to like & getrecommendations! Published in 2018 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2018.08.003
Abstract: Vemurafenib improves survival in advanced metastatic melanoma, but has rarely been associated with severe skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).1, 2 Dabrafenib is a BRAF inhibitor that shares a sulfonamide… read more here.
Keywords: vemurafenib induced; metastatic melanoma; epidermal necrolysis; toxic epidermal ... See more keywords
Melanoma: Time for adjuvant vemurafenib?
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2018.39
Abstract: ard-of-care procedure for stage IIC– III melanoma, most patients have a high risk of disease recurrence. Vemurafenib, a BRAF inhibitor with proven effectiveness in patients with advanced-stage or metastatic melanoma harbouring BRAFV600, has now been… read more here.
Keywords: melanoma; months months; disease; group ... See more keywords
Targeting MEK in vemurafenib-resistant hairy cell leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0270-2
Abstract: Hairy cell leukemia (HCL) is a chronic, incurable B cell malignancy that presents with splenomegaly, bone marrow infiltration, and cytopenias [1]. Long remissions are typically achieved with purine analogs such as cladribine, but most cases… read more here.
Keywords: braf; leukemia; resistance; vemurafenib ... See more keywords
Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Hematology and Oncology"
DOI: 10.1080/08880018.2022.2072986
Abstract: Abstract Almost half of the patients with Langerhans cell histiocytosis (LCH) are refractory to primary induction chemotherapy or undergo reactivation. The ideal treatment modality for refractory/relapsed LCH is yet not evidenced. This review aimed to… read more here.
Keywords: vemurafenib; langerhans cell; histiocytosis lch; lch ... See more keywords
Long-term Efficacy of Single-agent Vemurafenib for Pleomorphic Xanthoastrocytoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000001395
Abstract: Pleomorphic xanthoastrocytoma is a malignant brain tumor that has a good prognosis with complete resection but does not respond well to chemotherapy if there is residual tumor. BRAFV600E mutations are common in pleomorphic xanthoastrocytomas and… read more here.
Keywords: term efficacy; long term; efficacy single; pleomorphic xanthoastrocytoma ... See more keywords
Painful nipple hyperkeratosis secondary to vemurafenib
Sign Up to like & getrecommendations! Published in 2017 at "Dermatologic Therapy"
DOI: 10.1111/dth.12477
Abstract: Vemurafenib is a selected BRAF kinase inhibitor approved for treating metastatic or unresectable melanoma, which has numerous cutaneous side effects unfortunately, including three previously reported cases of asymptomatic areola and/or nipple hyperkeratosis. We present the… read more here.
Keywords: hyperkeratosis secondary; nipple hyperkeratosis; painful nipple; vemurafenib ... See more keywords
Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2019-000388
Abstract: Background Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related… read more here.
Keywords: administration; dress syndrome; drug; tocilizumab ... See more keywords